Beta-amyloid PET imaging for Alzheimer's diseaseIdentify, evaluate, and quantify beta-amyloid plaque
Several ground-breaking immunotherapy treatments have recently emerged that work to reduce beta-amyloid plaques that form in the brain and slow down cognitive decline in the early stages of Alzheimer's disease (AD). To qualify for these treatments, the presence of beta-amyloid plaque must be confirmed through diagnostic testing. Beta-amyloid PET imaging plays a critical role in the AD care pathway as it is one of the only modalities available to evaluate beta-amyloid plaque burden.
See our complete molecular imaging portfolio
1
Data on file.
2
Alzheimer's Association. FOR HEALTHCARE PROFESSIONALS. Frequently asked questions about beta-amyloid imaging. Available at https://www.alz.org/media/documents/health-care-pros-faqs-beta-amyloid-imaging.pdf. Accessed October 2023.
3
syngo.PET Amyloid Plaque is intended for use only with approved amyloid radiopharmaceuticals in the country of use. Users should review the drug labeling for approved uses.
The products and features mentioned herein are not commercially available in all countries. Future availability cannot be guaranteed.